Alpha emitting nuclides for targeted therapy.

Area of Science:

• Nuclear medicine and radiopharmaceutical research.
• Oncology and cancer therapeutics.
• Biomolecular targeting and drug delivery.

Background:

• Targeted alpha therapy (TAT) shows promise for cancer treatment by maximizing tumor cell cytotoxicity while minimizing off-target radiation.
• Key isotopes, actinium-225 and thorium-227, are crucial for TAT due to their decay properties and suitable half-lives.
• Actinium-225 offers unique potential as an in vivo radionuclide generator.

Purpose of the Study:

• To review the production and purification methods for actinium-225 and thorium-227.
• To discuss the labeling chemistry and biological studies of complexes involving these isotopes.
• To summarize current clinical investigations of targeted alpha therapy using these agents.

Main Methods:

• Literature review of scientific publications on actinium-225 and thorium-227 in targeted alpha therapy.
• Analysis of production, purification, and radiolabeling techniques.
• Synthesis of information on preclinical and clinical studies.

Main Results:

• Actinium-225 and thorium-227 possess favorable nuclear characteristics for TAT, including appropriate half-lives for biomolecular conjugation.
• Established methods exist for the production, purification, and radiolabeling of these isotopes for therapeutic applications.
• Ongoing biological and clinical studies demonstrate the potential of TAT with these isotopes for various cancers.

Conclusions:

• Actinium-225 and thorium-227 are highly promising isotopes for targeted alpha therapy.
• Further research and clinical trials are essential to fully realize the therapeutic potential of TAT.
• Optimized production, labeling, and delivery systems will enhance the efficacy and safety of these targeted radiotherapies.